Total | 2002–2005a | 2006–2009 | 2010–2013 | p for trend | |
---|---|---|---|---|---|
Penicillin-gentamicin | |||||
Total | 6.1 | 4.4 | 6.1 | 7.5 | 0.011 |
Community acquired | 4.3 | 2.2 | 5.7 | 5.0 | 0.22 |
Health care-associated | 6.7 | 7.4 | 5.8 | 7.2 | 0.16 |
Hospital acquired | 10.2 | 4.4 | 8.6 | 16.5 | 0.023 |
p for trend | 0.006 | 0.058 | 0.46 | 0.003 | |
Penicillin-gentamicin-metronidazole | |||||
Total | 3.5 | 1.9 | 3.0 | 5.2 | <0.001 |
Community acquired | 1.4 | 0.3 | 1.8 | 2.1 | 0.28 |
Health care-associated | 4.8 | 4.6 | 3.2 | 6.3 | 0.045 |
Hospital acquired | 6.9 | 2.2 | 6.2 | 11.7 | 0.026 |
p for trend | <0.001 | 0.007 | 0.15 | 0.001 | |
Piperacillin/tazobactam | |||||
Total (n = 1413) | 7.6 | 7.4 | 7.7 | 0.25 | |
Community acquired (n = 617) | 3.6 | 2.9 | 4.2 | 0.27 | |
Health care-associated (n = 612) | 8.8 | 9.4 | 8.4 | 0.31 | |
Hospital acquired (n = 184) | 8.8 | 9.4 | 17.0 | 0.31 | |
p for trend | <0.001 | <0.001 | <0.001 | ||
Piperacillin/tazobactam-gentamicin | |||||
Total (n = 1413) | 3.0 | 2.4 | 3.6 | 0.21 | |
Community acquired (n = 617) | 1.0 | 0.7 | 1.2 | 0.69 | |
Health care-associated (n = 612) | 3.3 | 3.2 | 3.3 | 0.98 | |
Hospital acquired (n = 184) | 9.2 | 4.9 | 12.6 | 0.12 | |
p for trend | <0.001 | 0.037 | <0.001 | ||
Piperacillin/tazobactam-gentamicin-metronidazole | |||||
Total (n = 1413) | 2.6 | 1.7 | 3.4 | 0.065 | |
Community acquired (n = 617) | 0.5 | 0.0 | 0.9 | 0.26 | |
Health care-associated (n = 612) | 2.9 | 2.5 | 3.3 | 0.64 | |
Hospital acquired (n = 184) | 8.7 | 4.9 | 11.7 | 0.12 | |
p for trend | <0.001 | 0.004 | <0.001 | ||
Imipenem | |||||
Community acquired | 1.1 | 1.6 | 0.7 | 0.9 | 0.59 |
Health care-associated | 6.5 | 9.1 | 5.8 | 5.7 | 0.39 |
Hospital acquired | 10.6 | 11.1 | 7.4 | 12.6 | 0.14 |
p for trend | <0.001 | <0.001 | 0.001 | <0.001 | |
Cefotaxime | |||||
Total | 17.8 | 17.5 | 18.7 | 17.3 | 0.68 |
Community acquired | 10.8 | 11.0 | 11.4 | 10.1 | 0.69 |
Health care-associated | 21.3 | 25.1 | 22.7 | 18.2 | 0.18 |
Hospital acquired | 31.4 | 25.6 | 29.6 | 37.9 | 0.31 |
p for trend | <0.001 | <0.001 | <0.001 | <0.001 | |
Ceftazidime | |||||
Total | 27.8 | 29.0 | 24.8 | 29.4 | 0.25 |
Community acquired | 18.5 | 20.2 | 15.4 | 19.6 | 0.42 |
Health care-associated | 31.3 | 36.0 | 28.2 | 31.3 | 0.37 |
Hospital acquired | 49.6 | 46.7 | 45.7 | 55.3 | 0.46 |
p for trend | <0.001 | <0.001 | <0.001 | <0.001 |